{"id":"NCT00538863","sponsor":"INSYS Therapeutics Inc","briefTitle":"Long-term Safety and Efficacy Study of Fentanyl Sublingual Spray for the Treatment of Breakthrough Cancer Pain","officialTitle":"Open-label Multi-center Safety Trial of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-12","primaryCompletion":"2010-10","completion":"2010-10","firstPosted":"2007-10-03","resultsPosted":"2013-10-11","lastUpdate":"2013-10-11"},"enrollment":319,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"SUPPORTIVE_CARE"},"conditions":["Cancer","Pain"],"interventions":[{"type":"DRUG","name":"Fentanyl sublingual spray","otherNames":[]}],"arms":[{"label":"Fentanyl sublingual spray titration","type":"EXPERIMENTAL"},{"label":"Fentanyl sublingual spray maintenance","type":"EXPERIMENTAL"}],"summary":"The purpose of this study was to assess the 90-day safety of fentanyl sublingual spray for the treatment of breakthrough cancer pain in subjects on around-the-clock opioids for their persistent cancer pain.","primaryOutcome":{"measure":"Percentage of Patients That Experienced 1 or More Adverse Events","timeFrame":"Baseline to end of the study (up to 116 days)","effectByArm":[{"arm":"Fentanyl Sublingual Spray Titration","deltaMin":59,"sd":null},{"arm":"Fentanyl Sublingual Spray Maintenance","deltaMin":80.7,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":52,"countries":["United States","Canada","India"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":33,"n":229},"commonTop":["Malignant neoplasm progression","Vomiting","Nausea","Constipation","Oedema peripheral"]}}